
First clinical results from AKIR001 to be presented at EANM 2026
Akiram Therapeutics’ abstract presenting the first clinical results from the ongoing first-in-human trial has been selected as a Top Rated Oral Presentation (TROP) at EANM 2026. The study is evaluating 177Lu-AKIR001 in patients with irresectable or metastatic CD44v6-positive solid tumours who have no remaining standard treatment options. … Read More



